MedTrace Logo

Patients Treated for SCID (1968-Present)

NCT01346150 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1007

Last updated 2020-11-12

No results posted yet for this study

Summary

Individuals with a past diagnosis of severe combined immune deficiency (including many cases of "leaky SCID", Omenn syndrome, and reticular dysgenesis) who have undergone blood and marrow transplant, gene therapy, or enzyme replacement in the past may be eligible for this study. The purpose of study is to look backwards at what has already been done in the. Over 800 patients with SCID are expected to be enrolled, making this one of the largest studies ever to describe outcomes for patients with SCID treated at many different hospitals around North America.

Conditions

  • SCID
  • ADA-SCID
  • XSCID
  • Leaky SCID
  • Omenn Syndrome
  • Reticular Dysgenesis

Sponsors & Collaborators

  • Primary Immune Deficiency Treatment Consortium (PIDTC)

    collaborator OTHER

  • National Center for Advancing Translational Sciences (NCATS)

    collaborator NIH

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Elie Haddad, MD, PhD · University of Montréal, CHU Sainte-Justine

  • Richard J. O'Reilly, MD · Memorial Sloan Kettering Cancer Center

  • Morton J. Cowan, MD · University of California, San Francisco

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-15
Primary Completion
2023-08-31
Completion
2023-08-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01346150 on ClinicalTrials.gov